# Fluorine F 18 EF5 Positron Emission Tomography in Assessing Hypoxia in Patients With Newly Diagnosed Stage I, Stage II, Stage III, or Stage IV Head or Neck Squamous Cell Cancer of the Oral Cavity, Oropharynx, and Larynx

> **NCT01020097** · NA · COMPLETED · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 5 (actual)

## Conditions studied

- Squamous Cell Carcinoma

## Interventions

- **DRUG:** fluorine F18 EF5
- **PROCEDURE:** immunohistochemistry staining method
- **PROCEDURE:** biopsy
- **PROCEDURE:** Positron Emission tomography

## Key facts

- **NCT ID:** NCT01020097
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2020-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01020097

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01020097, "Fluorine F 18 EF5 Positron Emission Tomography in Assessing Hypoxia in Patients With Newly Diagnosed Stage I, Stage II, Stage III, or Stage IV Head or Neck Squamous Cell Cancer of the Oral Cavity, Oropharynx, and Larynx". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01020097. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*